Amicus Therapeutics, Inc. (FOLD) - Company Revenue

Amicus Therapeutics (FOLD) leverages the digitalization of bioanalysis and AI to drive efficiency and reduce costs. The company's commercial revenue clearly confirms this growth, with the indicator currently standing at 0.63. Development relies on partnerships with geneticists and patient funds. High margins from monopoly products within the narrow niche of rare metabolic pathologies ensure the long-term financial stability of the business.

FOLD Amicus Corp: Company Revenue in the range 07/04/2022 - 05/09/2026

Analytical breakdowns for Amicus Therapeutics

- price and consensus price forecast:

Stock Price Amicus Corp|FOLD - Analyst Consensus Forecast

- market capitalization indicators:

Market Value Amicus Therapeutics, Inc.|FOLD - Total Company Value

- book capitalization information:

Net Asset Value per Share Amicus Therapeutics|FOLD - Company Book Value|Market Value to Book Value Ratio amicusrx.com|FOLD - Company Total Assets

- company liabilities and liquidity data:

- business earnings and investment ratios data:

FOLD - Net Profit|Company Profit Forecast Amicus Therapeutics|FOLD - P/E Multiple|Projected Price to Earnings amicusrx.com|FOLD - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Amicus Therapeutics, Inc.|FOLD - Profit before payment of interest, taxes and amortization|Net earnings per share for the last four quarters Amicus Therapeutics|FOLD - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months amicusrx.com|FOLD - Net earnings per share growth this year|Projected earnings per share increase next year Amicus Therapeutics

- sales volume and revenue indicators:

FOLD - Revenue and Sales Volume|Company Future Revenue Amicus Corp|FOLD - P/S Multiple|Market Cap to Future Revenue Ratio Amicus Therapeutics, Inc.

Comprehensive company analysis:FOLD Amicus Corp

Amicus Therapeutics (FOLD) specializes in therapies for rare metabolic pathologies, ensuring high margins through its monopoly position, which directly drives revenue dynamics. By analyzing the company's sales volume on the GURU.Markets platform, investors can assess the aggregate cash flow from sales, which helps mitigate US market cycle risks and confirms sustained demand for its unique drugs.

Key competitors